These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


560 related items for PubMed ID: 24177376

  • 1. Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response.
    Gordon SC, Reddy KR, Jacobson IM, Poordad F, Bronowicki JP, Bacon B, Buti M, Hu KQ, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Lawitz EJ.
    J Clin Gastroenterol; 2014; 48(5):435-43. PubMed ID: 24177376
    [Abstract] [Full Text] [Related]

  • 2. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.
    Flamm SL, Lawitz E, Jacobson I, Bourlière M, Hezode C, Vierling JM, Bacon BR, Niederau C, Sherman M, Goteti V, Sings HL, Barnard RO, Howe JA, Pedicone LD, Burroughs MH, Brass CA, Albrecht JK, Poordad F.
    Clin Gastroenterol Hepatol; 2013 Jan; 11(1):81-87.e4; quiz e5. PubMed ID: 23064222
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Boceprevir for previously treated chronic HCV genotype 1 infection.
    Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R, HCV RESPOND-2 Investigators.
    N Engl J Med; 2011 Mar 31; 364(13):1207-17. PubMed ID: 21449784
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
    Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK, SPRINT-1 investigators.
    Lancet; 2010 Aug 28; 376(9742):705-16. PubMed ID: 20692693
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.
    Liu CH, Liu CJ, Huang CF, Lin JW, Dai CY, Liang CC, Huang JF, Hung PH, Tsai HB, Tsai MK, Lee CY, Chen SI, Yang SS, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Yu ML, Kao JH.
    Gut; 2015 Feb 28; 64(2):303-11. PubMed ID: 24747867
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.
    Jacobson IM, Marcellin P, Zeuzem S, Sulkowski MS, Esteban R, Poordad F, Bruno S, Burroughs MH, Pedicone LD, Boparai N, Deng W, DiNubile MJ, Gottesdiener KM, Brass CA, Albrecht JK, Bronowicki JP.
    Hepatology; 2012 Aug 28; 56(2):567-75. PubMed ID: 22619063
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan.
    Hsieh MH, Yeh ML, Su TH, Liu TW, Huang CF, Huang CI, Wang SC, Huang JF, Dai CY, Kao JH, Chuang WL, Chen PJ, Liu CJ, Yu ML.
    J Formos Med Assoc; 2018 Jun 28; 117(6):497-504. PubMed ID: 28694000
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study.
    Fernández-Rodríguez CM, Morillas RM, Masnou H, Navarro JM, Bárcena R, González JM, Martín-Martín L, Poyato A, Miquel-Planas M, Jorquera F, Casanovas T, Salmerón J, Calleja JL, Solà R, Alonso S, Planas R, Romero-Gomez M.
    Gastroenterol Hepatol; 2014 Jan 28; 37(1):1-8. PubMed ID: 24360571
    [Abstract] [Full Text] [Related]

  • 17. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P, Yang JM, Hou W, Song SD, Wang L, Lu W.
    Eur J Gastroenterol Hepatol; 2013 May 28; 25(5):601-5. PubMed ID: 23263720
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy.
    Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T, Heathcote EJ, Gonçales F, Diago M, Craxi A, Silva M, Bedossa P, Mukhopadhyay P, Griffel L, Burroughs M, Brass C, Albrecht J, Epic Study Group.
    Gastroenterology; 2009 May 28; 136(5):1618-28.e2. PubMed ID: 19208349
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 28.